The Galien Foundation的动态

Looking forward to moderating this conversation on the importance of eliminating policy barriers to diversifying clinical trials, hosted by National Minority Quality Forum this Friday alongside leaders from American Cancer Society Cancer Action Network (ACS CAN) and Caregiver Action Network Please register below and share with your networks! https://lnkd.in/ewh3SgzR Clinical trials are key to advancing new standards of care that can improve survival and quality of life for people with cancer. However, cost to trial participants is often a barrier to their enrollment. This conversation will dive into the background on the clinical trials landscape and present policy solutions that will work to eliminate some of these barriers, in particular, the Clinical Trials Modernization Act (H.R. 8412) (CTMA) CTMA would increase access to clinical trials by allowing clinical trial sponsors to provide financial support to patients for costs associated with their trial participation, including medical cost-sharing like copays, and non-medical expenses such as travel, parking, food, and lodging. The leaders on this panel will discuss the legislation, as well as provide a call to action for how organizations and individuals can advocate for policies that actively work to increase diverse participation in clinical trials, and will also provide resources and tools to help individuals navigate the often complex clinical trials landscape.

The pan-Canadian Pharmaceutical Alliance (pCPA) may not be known to many Canadians but, nonetheless, so many Canadian patients are impacted by their work in profound ways. Last week, my colleague, Mark Smithyes, MBA joined the pCPA's CEO, Douglas Clark, in a discussion that touched on the challenges of improving access for patients to new and innovative medicines while supporting payors' interests in optimizing value in drug spending. In many ways, Canada has been a leader in examining this question of "value", particularly our early leadership in embracing the Health Technology Assessments (HTA) framework and, later, in pioneering Product Listing Agreements (PLA) that, together, look beyond the question of PRICE and go deeper into an appreciation of VALUE, both to patients and health systems alike. This has not been easy, and challenges remain, but I have to say that there have been some amazing examples of how industry, payors, governments have been able to bring innovation and goodwill to the table in the interests of finding common ground and finding the "win" for patients. No doubt, serious challenges lie ahead, but the willingness of actors like Douglas Clark and others to speak openly and frankly about those challenges at a forum like this is not only a positive sign, but also speaks volumes about the kind of unique ecosystem that Canada -- and Canadians -- have painstakingly created over the years.

It’s a very useful step for publishing such guidance in #clinical trial practice #WHO

New guidance for best practices in clinical trials has been released by the WHO. I think we should keep this guidance in mind while planning to conduct our clinical trials! #ClinicalTrials

Strengthening clinical trials, whether observational/non-interventional or interventional, is crucial for generating high-quality evidence on health interventions. This improvement not only enhances research quality and education but also plays a vital role in developing interventions that can prevent, mitigate, or cure various health issues.

Since the pioneering of clinical trials by James Lind in 1747, healthcare and life science researchers have played a foundational role in supporting clinical outcomes through disease investigation and cure discovery. GRN is proud to be a leader in clinical trial innovation by bringing new research opportunities to patients around the country and working with health systems around the country dedicated to improving care for all communities they serve. By leveraging data, the entire GRN network is contributing to robust real-world insights that impact health care of the future. Together, we’re continuing the mission to leverage clinical trials to improve the quality of care, cure diseases, and save lives. Learn more: https://lnkd.in/gRV_6Y3x #ClinicalTrialsDay #RealWorldData #ClinicalResearch #GRN

Check out our paper in JAMA today! https://lnkd.in/dMetaAE2 We analyzed disease awareness campaigns officially recognized by WHO, Cochrane or the US government. We found that campaigns were often more promotional than informative; highlighting benefit much more than harm - and at least two thirds had commercial involvement but rarely disclosed this clearly. If campaigns intend to inform the public rather than promote products, they should strive for balanced messaging that quantify both benefits and harms - and they should transparently disclose any financial interests in their messaging. From team: Loai Albarqouni - Mary O' Keeffe - Karsten Juhl J?rgensen - Steven Woloshin Check out the Global Center for Sustainable Healthcare at: https://lnkd.in/dw2gK5MK G?teborgs universitet Sahlgrenska Academy at University of Gothenburg

Taking ownership of your health and doing what you can to lead a better life is important to all, especially in the clinical research industry. For World Health Day, Judith Iancu, FSP Program Manager, shares how this day resonates with the clinical research industry. #WorldHealthDay2024 #WorldHealthDay #ClinicalResearch

??Did you know that up to 100 million people in Europe suffer from CKD-aP, and 300 million are at risk? With an aging population these numbers are on the rise and it is time to take action!? ? Let’s start by addressing the lack of diagnosis and management leads to difficulties in treatment and reporting. Our White Paper identifies collaboration within international, European, and national patient associations as a crucial element ??. To tackle this current health challenge, it is key to implement effective awareness campaigns and support those affected by this condition.? ? Together, we can shine a light on CKD-aP patients??! By joining forces, we ensure patients receive the support and treatment they need through ongoing education and knowledge-sharing.? ? Join us in our aim to raise awareness, promote positive change, and improve the lives of CKD-aP patients around Europe. ?? Be part of the movement by sharing our insightful White Paper and spreading the word.? ? Together, we can make a difference!? https://bit.ly/3J3n5hc????